Wide Ranks

AIM

AIM ImmunoTech Inc.

0.2280

Top Statistics
Market Cap 14 M Forward PE -0.5846 Revenue Growth 19.00 %
Current Ratio 1.17 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.1930 Enterprise / Revenue 30.05 Price To Sales Trailing12 Months 72.26
Profitability
Profit Margins 0.00 % Operating Margins -7388.00 %
Balance Sheet
Total Cash 10 M Total Cash Per Share 0.1760 Total Debt 3 M
Total Debt To Equity 55.05 Current Ratio 1.17 Book Value Per Share 0.1940
All Measures
Short Ratio 163.00 % Message Board Id finmb_97799 Fax 352 480 4620
Shares Short Prior Month 590329 Return On Equity -1.55 City Ocala
Uuid 527cb9d6-69af-3507-a5c0-21ee7cf37c07 Previous Close 0.2250 First Trade Date Epoch Utc 837 M
Book Value 0.1940 Beta -0.3630 Total Debt 3 M
Volume 606305 Price To Book 1.18 Last Split Date 1 B
Fifty Two Week Low 0.1600 Total Cash Per Share 0.1760 Total Revenue 201000
Shares Short Previous Month Date 1 B Target Median Price 3.00 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Operating Margins -7388.00 %
Target Mean Price 3.00 Net Income To Common -28045000 Ask 0.2447
Short Percent Of Float 0.0085 Implied Shares Outstanding 63 M Last Fiscal Year End 1 B
Trailing Peg Ratio None Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 10 M Next Fiscal Year End 1 B Revenue Per Share 0.0040
Held Percent Insiders 0.0857 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.2250 Target Low Price 1.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.2500 Open 0.2308
Free Cashflow -16044000 State FL Dividend Yield 0.00 %
Return On Assets -0.8004 Time Zone Short Name EST Trailing Eps -0.4700
Day Low 0.2210 Address1 2117 SW Highway 484 Shares Outstanding 63 M
Price Hint 4 Target High Price 5.00 Website https://aimimmuno.com
52 Week Change -0.5106 Average Volume 423312 Forward Eps -0.4100
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 113.80 %
Last Split Factor 1:44 Regular Market Day High 0.2439 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 55.05 Fifty Two Week High 0.6200
Day High 0.2439 Shares Short 491374 Regular Market Open 0.2308
Industry Key biotechnology Bid 0.2300 Earnings Growth 0.00 %
Enterprise To Revenue 30.05 Revenue Growth 19.00 % Shares Percent Shares Out 0.0077
Operating Cashflow -23252000 Currency USD Time Zone Full Name America/New_York
Market Cap 14 M Is_nasdaq_100 False Zip 34473
Quote Type EQUITY Industry Biotechnology Long Name AIM ImmunoTech Inc.
Regular Market Day Low 0.2210 Held Percent Institutions 0.1407 Current Price 0.2280
Enterprise To Ebitda -0.1930 Financial Currency USD Current Ratio 1.17
Gross Margins 71.14 % Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 48 M Two Hundred Day Average 0.3543
Ir Website http://www.hemispherx.net/content/investor/ Enterprise Value 6 M Price To Sales Trailing12 Months 72.26
Forward PE -0.5846 Regular Market Volume 606305 Ebitda -31359000
Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.

The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease.

AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation.

The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.

AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.